Treatment of hypoparathyroidism
- PMID: 30551988
- DOI: 10.1016/j.beem.2018.12.002
Treatment of hypoparathyroidism
Abstract
The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1-84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1-84) appears to represent a new option in patients with chronic hypoparathyroidism "resistant" to conventional treatment.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment in
-
Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.Endocrine. 2020 Jun;68(3):475-478. doi: 10.1007/s12020-020-02383-5. Epub 2020 Jun 12. Endocrine. 2020. PMID: 32533508 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources